SOST and bone disorder: Whereas several studies have investigated associations of serum sclerostin with disorders of bone [43–45], vascular disease [46], chronic kidney disease (CKD) [47–50], and mortality [51–55], so far, no prospective or controlled studies are available concerning the role of sclerostin in nephrolithiasis.